The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

asmaa salama ibrahim

Status: Completed

Conditions: Acute Myeloid Leukemia (AML); Ewing Sarcoma

Study type: Observational

Funder types: Other

Identifiers

NCT06659224

A275

Details and patient eligibility

About

Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.

Enrollment: 2,631 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with Ewing sarcoma
• Latency exclusion period of 6 months
• Sequence 0 or 1

Exclusion criteria

• patients lacking age documentation or age reported only on death certificates or autopsies